103 related articles for article (PubMed ID: 25595125)
1. Solid-state interactions at the core-coat interface: physicochemical characterization of enteric-coated omeprazole pellets without a protective sub-coat.
Sharma VD; Akocak S; Ilies MA; Fassihi R
AAPS PharmSciTech; 2015 Aug; 16(4):934-43. PubMed ID: 25595125
[TBL] [Abstract][Full Text] [Related]
2. Solid state interactions between the proton pump inhibitor omeprazole and various enteric coating polymers.
Stroyer A; McGinity JW; Leopold CS
J Pharm Sci; 2006 Jun; 95(6):1342-53. PubMed ID: 16625655
[TBL] [Abstract][Full Text] [Related]
3. Effect of Elevated pH on the Commercial Enteric-Coated Omeprazole Pellets Resistance: Patent Review and Multisource Generics Comparison.
Mohylyuk V; Yerkhova A; Katynska M; Sirko V; Patel K
AAPS PharmSciTech; 2021 Jun; 22(5):188. PubMed ID: 34159427
[TBL] [Abstract][Full Text] [Related]
4. Instantaneous enteric nano-encapsulation of omeprazole: pharmaceutical and pharmacological evaluation.
Bendas ER; Abdelbary AA
Int J Pharm; 2014 Jul; 468(1-2):97-104. PubMed ID: 24746414
[TBL] [Abstract][Full Text] [Related]
5. Broadband Acoustic Resonance Dissolution Spectroscopy (BARDS): A rapid test for enteric coating thickness and integrity of controlled release pellet formulations.
Alfarsi A; Dillon A; McSweeney S; Krüse J; Griffin B; Devine K; Sherry P; Henken S; Fitzpatrick S; Fitzpatrick D
Int J Pharm; 2018 Jun; 544(1):31-38. PubMed ID: 29655796
[TBL] [Abstract][Full Text] [Related]
6. Water-mediated solid-state transformation of a polymorphic drug during aqueous-based drug-layer coating of pellets.
Lust A; Lakio S; Vintsevits J; Kozlova J; Veski P; Heinämäki J; Kogermann K
Int J Pharm; 2013 Nov; 456(1):41-8. PubMed ID: 23994016
[TBL] [Abstract][Full Text] [Related]
7. Study of the recrystallization in coated pellets - effect of coating on API crystallinity.
Nikowitz K; Pintye-Hódi K; Regdon G
Eur J Pharm Sci; 2013 Feb; 48(3):563-71. PubMed ID: 23291037
[TBL] [Abstract][Full Text] [Related]
8. Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified beta-cyclodextrin.
Figueiras A; Carvalho RA; Ribeiro L; Torres-Labandeira JJ; Veiga FJ
Eur J Pharm Biopharm; 2007 Sep; 67(2):531-9. PubMed ID: 17451924
[TBL] [Abstract][Full Text] [Related]
9. Looking for the interactions between omeprazole and amoxicillin in a disordered phase. An experimental and theoretical study.
Russo MG; Sancho MI; Silva LM; Baldoni HA; Venancio T; Ellena J; Narda GE
Spectrochim Acta A Mol Biomol Spectrosc; 2016 Mar; 156():70-7. PubMed ID: 26654963
[TBL] [Abstract][Full Text] [Related]
10. Enhanced oral bioavailability of novel mucoadhesive pellets containing valsartan prepared by a dry powder-coating technique.
Cao QR; Liu Y; Xu WJ; Lee BJ; Yang M; Cui JH
Int J Pharm; 2012 Sep; 434(1-2):325-33. PubMed ID: 22688251
[TBL] [Abstract][Full Text] [Related]
11. Diffusion of a freely water-soluble drug in aqueous enteric-coated pellets.
Guo HX; Heinämäki J; Yliruusi J
AAPS PharmSciTech; 2002; 3(2):E16. PubMed ID: 12916953
[TBL] [Abstract][Full Text] [Related]
12. Formulation and evaluation of sustained release enteric-coated pellets of budesonide for intestinal delivery.
Raval MK; Ramani RV; Sheth NR
Int J Pharm Investig; 2013 Oct; 3(4):203-11. PubMed ID: 24350040
[TBL] [Abstract][Full Text] [Related]
13. Analytical characterization of an orally-delivered peptide pharmaceutical product.
Kelley WP; Chen S; Floyd PD; Hu P; Kapsi SG; Kord AS; Sun M; Vogt FG
Anal Chem; 2012 May; 84(10):4357-72. PubMed ID: 22497462
[TBL] [Abstract][Full Text] [Related]
14. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
[TBL] [Abstract][Full Text] [Related]
15. Development and evaluation of omeprazole pellets fabricated by sieving-spheronization and extrusion - spheronization process.
Karim S; Baie SH; Hay YK; Bukhari NI
Pak J Pharm Sci; 2014 May; 27(3):425-38. PubMed ID: 24811797
[TBL] [Abstract][Full Text] [Related]
16. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
Liu F; Shokrollahi H
Int J Pharm; 2015 May; 485(1-2):152-9. PubMed ID: 25746736
[TBL] [Abstract][Full Text] [Related]
17. SEM/EDX and confocal microscopy analysis of novel and conventional enteric-coated systems.
Liu F; Lizio R; Schneider UJ; Petereit HU; Blakey P; Basit AW
Int J Pharm; 2009 Mar; 369(1-2):72-8. PubMed ID: 19061944
[TBL] [Abstract][Full Text] [Related]
18. Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies.
Missaghi S; Young C; Fegely K; Rajabi-Siahboomi AR
Drug Dev Ind Pharm; 2010 Feb; 36(2):180-9. PubMed ID: 20070183
[TBL] [Abstract][Full Text] [Related]
19. Degradation of omeprazole induced by enteric polymer solutions and aqueous dispersions: HPLC investigations.
Riedel A; Leopold CS
Drug Dev Ind Pharm; 2005 Jan; 31(2):151-60. PubMed ID: 15773282
[TBL] [Abstract][Full Text] [Related]
20. Tableting and stability evaluation of enteric-coated omeprazole pellets.
Türkoğlu M; Varol H; Celikok M
Eur J Pharm Biopharm; 2004 Mar; 57(2):279-86. PubMed ID: 15018985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
